目的 探討血滯通膠囊聯(lián)合阿昔莫司治療高脂血癥的臨床療效。方法 選取2015年2月-2016年2月在磁縣人民醫(yī)院進(jìn)行治療的高脂血癥患者82例，根據(jù)治療方案的差別分為對(duì)照組（41例）和治療組（41例）。對(duì)照組口服阿昔莫司膠囊，1粒/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服血滯通膠囊，1粒/次，3次/d。兩組患者均連續(xù)治療12周。比較兩組患者治療前后臨床療效、血脂水平、血清炎性因子水平和內(nèi)皮功能因子改變。結(jié)果 治療后，對(duì)照組總有效率為80.49%，顯著低于治療組的95.12%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組總膽固醇（TC）、低密度脂蛋白（LDL-C）和三酰甘油（TG）均顯著下降，而高密度脂蛋白（HDL-C）升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者上述血脂水平優(yōu)于對(duì)照組（P<0.05）。治療后，兩組患者血清超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-6（IL-6）和腫瘤壞死因子-α（TNF-α）水平均顯著下降（P<0.05）；且治療組患者下降比對(duì)照組更顯著（P<0.05）。治療后，兩組患者血清NO顯著升高，ET-1水平顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組NO和ET-1水平優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 血滯通膠囊聯(lián)合阿昔莫司治療高脂血癥效果顯著，可有效降低機(jī)體炎性因子水平，改善血管內(nèi)皮功能因子，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Xuezhitong Capsules combined with acipimox in treatment of hyperlipidemia. Methods Patients (82 cases) with hyperlipidemia in Cixian People's Hospital from February 2015 to February 2016 were divided into control (41 cases) and treatment (41 cases) groups based on different treatments. Patients in the control group were po administered with Acipimox Capsules, 1 grain/time, three times daily. Patients in the treatment group were po administered with Xuezhitong Capsules on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy, the change of blood lipid level, serum inflammatory factors and endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control grop was 80.49%, which was significantly lower than 95.12% in the treatment group, and there was difference between two groups (P<0.05). After treatment, TC, LDL-C, and TG in two groups were significantly decreased, but HDL-C was significantly increased, and the difference was statistically significant in the same group (P<0.05). And the blood lipid level in the treatment group was significantly better than those in the control group (P<0.05). After treatment, hs-CRP, IL-6, and TNF-α level in two groups was significantly decreased (P<0.05). And these indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, serum NO level in two groups was significantly increased, ET-1 level was significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the improvement of these indicators in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Xuezhitong Capsules combined with acipimox has a significant effect in treatment of hyperlipidemia, can reduce the inflammatory factors level and improve endothelial function, which has a certain clinical application value.